Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of mifamurtide versus sorafenib-containing standard therapy in high-risk osteosarcoma
2026-525223-24-00Phase 2Authorised
- Sponsor
- Institute of Mother and Child
- Start
- Apr 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of mifamurtide and sorafenib in osteosarcoma (OS) (2 arms), sponsored by Institute of Mother and Child. Primary endpoint: Event-free survival. Planned start Apr 2026; status: authorised.
02
Drugs
mifamurtidesorafenib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2026-525223-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525223-24-00.